logo
logo
ZTS stock ticker logo

Zoetis Inc.

NYSE•ZTS
CEO: Ms. Kristin C. Peck
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2013-02-01
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
連絡先情報
10 Sylvan Way, Parsippany, NJ, 07054, United States
973-822-7000
www.zoetis.com
時価総額
$52.79B
PER (TTM)
19.6
35.9
配当利回り
1.7%
52週高値
$172.23
52週安値
$115.25
52週レンジ
8%
順位6
7.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 7.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$2.39B+0.00%
直近4四半期の推移

EPS

$1.38+0.00%
直近4四半期の推移

フリーCF

$732.00M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Income Rises 8% Net income attributable to Zoetis reached $2,673M in 2025, marking an 8% increase compared to 2024 results.
Total Revenue Grows 2% Total revenue was $9,467M in 2025, reflecting 2% growth driven by 4% price increases globally.
Companion Animal Sales Strong Companion animal revenue grew 5% to $6,587M, led by Simparica and Apoquel franchises performance.
Diluted EPS Up 10% Diluted EPS reached $6.02 for 2025, showing a 10% improvement over the prior year's $5.47.

リスク要因

Generic Competition Erodes Sales Generic competition caused Draxxin sales to decline 66% in the U.S. market, impacting overall revenue stability.
Livestock Revenue Declines Livestock revenue fell 5% to $2,764M in 2025, partially due to the MFA divestiture impact.
Substantial Debt Obligations Total unsecured indebtedness stands at $9.2B, increasing vulnerability to adverse economic and industry conditions.
Regulatory Scrutiny Increasing Increased regulatory scrutiny concerning antibacterial use and environmental impact may necessitate additional time and resources.

見通し

ERP Transition Underway Multi-year ERP system update is progressing, aiming for seamless financial consolidation and regulatory compliance in 2026.
FY Alignment Expected 2026 Expect to eliminate the one-month lag for International Subsidiaries in 2026, aligning year-ends to December 31.
Continued Innovation Focus Strategy emphasizes leading through innovation across the diverse portfolio, leveraging R&D capabilities and external collaborations.
Capital Allocation Priorities Board authorized up to $6B share repurchase program; $2.4B remains available as of year-end 2025.

同業比較

売上高 (TTM)

COR stock ticker logoCOR
$325.78B
+7.4%
CI stock ticker logoCI
$274.95B
+11.3%
ELV stock ticker logoELV
$199.13B
+12.6%

粗利益率 (最新四半期)

ARGX stock ticker logoARGX
89.3%
-53.8pp
REGN stock ticker logoREGN
85.0%
+3.3pp
ALNY stock ticker logoALNY
75.6%
+1.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
GSK$110.59B14.537.2%29.0%
REGN$80.49B17.714.8%6.7%
CI$69.69B11.614.5%19.9%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.4%
緩やかな成長
4四半期純利益CAGR
-1.5%
収益性の安定
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月30日
|
EPS:$1.61
|
売上高:$2.31B
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし